<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04983043</url>
  </required_header>
  <id_info>
    <org_study_id>TSL-TCM-QSYQDW-HFrEF-Ⅱ</org_study_id>
    <nct_id>NCT04983043</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Reduced Ejection Fraction (Syndrome of Qi Deficiency and Blood Stasis) Due to Coronary Heart Disease</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-parallel Controlled, Standardise-loaded Ⅱ Clinical Trial of Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Reduced Ejection Fraction (Syndrome of Qi Deficiency and Blood Stasis) Due to Coronary Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tasly Pharmaceutical Group Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tasly Pharmaceutical Group Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety and the best effective dose of Qishen Yiqi&#xD;
      Drop Pills in the treatment of chronic heart failure with decreased ejection fraction of CHD&#xD;
      (Qi deficiency and blood stasis syndrome).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6-Minutes-Walking-Test (6MWT) in week 12</measure>
    <time_frame>Baseline to weeks 12</time_frame>
    <description>Change from baseline to weeks 12 in exercise capacity as measured by the 6-Minutes-Walking-Test (6MWT) distance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-Minutes-Walking-Test (6MWT) in weeks 4 and 8</measure>
    <time_frame>Baseline to weeks 4 and 8</time_frame>
    <description>Change from baseline to weeks 4 and 8 in exercise capacity as measured by the 6-Minutes-Walking-Test (6MWT) distance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA classification</measure>
    <time_frame>Baseline to weeks 4,8 and 12</time_frame>
    <description>Percentage of subjects whose NYHA classification improved/worsened/remained unchanged from baseline to weeks 4,8 and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Traditional Chinese Medicine Syndrome Score</measure>
    <time_frame>Baseline to weeks 4,8 and 12</time_frame>
    <description>Change from baseline to weeks 4,8 and 12 in Traditional Chinese Medicine Syndrome Score. There were 3 clinical primary symptoms, 4 clinical secondary symptoms, tongue picture and pulse condition evaluated as TCM symptoms, which was defined as TCM syndrome score. The standard of TCM primary symptoms scored as without 0, light 2, medium 4, heavy 6 points. The standard of TCM secondary symptoms scored as without 0, with 1 points. Tongue picture and pulse condition did not count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea, weakness, edema</measure>
    <time_frame>Baseline to weeks 4,8 and 12</time_frame>
    <description>Symptom disappearance rate(dyspnea, weakness, edema) from baseline to weeks 4,8 and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiogram results</measure>
    <time_frame>Baseline to weeks 4,8 and 12</time_frame>
    <description>Change from baseline to weeks 4,8 and 12 in left ventricular end diastolic diameter(LVEDD) measured by echocardiography;&#xD;
Change from baseline to weeks 4,8 and 12 in left ventricular end diastolic volume(LVEDV) measured by echocardiography;&#xD;
Change from baseline to weeks 4,8 and 12 in left ventricular end systolic volume(LVESV) measured by echocardiography;&#xD;
Change from baseline to weeks 4,8 and 12 in left ventricular ejection fraction(LVEF) measured by echocardiography;&#xD;
Change from baseline to weeks 4,8 and 12 in stroke volume(SV) measured by echocardiography;&#xD;
Change from baseline to weeks 4,8 and 12 in cardiac output(CO) measured by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>Baseline to weeks 4,8 and 12</time_frame>
    <description>Change from baseline to weeks 4,8 and 12 in NT-proBNP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minnesota Living With Heart Failure Questionnaire(MLHFQ)</measure>
    <time_frame>Baseline to weeks 4,8 and 12</time_frame>
    <description>Change from baseline to weeks 4,8 and 12 in Minnesota Living With Heart Failure Questionnaire(MLHFQ). The MLHFQ is a self-administered questionnaire for patients with HF, comprising 21 items representing different degrees of impact of HF on health-related quality of life. Every item in this questionnaire scores from 0 (none) to 5 (very much) and the total items score from 0 (none) to 105 (very much).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular adverse events</measure>
    <time_frame>Week 12</time_frame>
    <description>To determine whether the incidence of cardiovascular adverse events during the study period was superior to placebo.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Oxyhemoglobin saturation</measure>
    <time_frame>Week 12</time_frame>
    <description>To determine whether the oxyhemoglobin saturation is improved from baseline to week 12 after treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Grasp strength body mass index test</measure>
    <time_frame>Week 12</time_frame>
    <description>To determine whether the grasp strength body mass index is improved from baseline to week 12 after treatment.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">228</enrollment>
  <condition>Chronic Heart Failure With Reduced Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose Qishenyiqi Dripping Pills, 3 bags, take orally after meals, 3 times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose Qishenyiqi Dripping Pills, 3 bags, take orally after meals, 3 times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Qishenyiqi Dripping Pills placebo, 3 bags, take orally after meals, 3 times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose Qishenyiqi Dripping Pills 3 bags</intervention_name>
    <description>Low dose Qishenyiqi Dripping Pills contain Qishenyiqi dripping pills 2 bags(0.52g dripping pills per bag) and Qishenyiqi dripping pills placebo 1 bag(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks</description>
    <arm_group_label>Low dose group</arm_group_label>
    <other_name>Low dose group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose Qishenyiqi Dripping Pills 3 bags</intervention_name>
    <description>High dose Qishenyiqi Dripping Pills contain Qishenyiqi dripping pills 3 bags(0.52g dripping pills per bag),take orally after meals, 3 times a day for 12weeks</description>
    <arm_group_label>High dose group</arm_group_label>
    <other_name>High dose group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qishenyiqi Dripping Pills placebo 3 bags</intervention_name>
    <description>Qishenyiqi Dripping Pills placebo contain Qishenyiqi dripping pills placebo 3 bags(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Placebo group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Conformed to the diagnostic criteria of CHD and chronic heart failure&#xD;
&#xD;
          -  Conformed to the TCM syndrome differentiation standard of chronic heart failure&#xD;
             syndrome of Qi deficiency and blood stasis&#xD;
&#xD;
          -  Male or female subjects aged ≥ 40 years and ≤75 years&#xD;
&#xD;
          -  LVEF&lt;45%(modified Simpson method)&#xD;
&#xD;
          -  NYHAⅡ-Ⅲ&#xD;
&#xD;
          -  Received standardized drug therapy for chronic heart failure at least 2 weeks before&#xD;
             randomization, and did not receive intravenous therapy (vasoactive drugs, diuretics)&#xD;
             within 2 weeks without adjustment of dose&#xD;
&#xD;
          -  Ability to understand the requirements of the study and willingness to provide written&#xD;
             informed consent&#xD;
&#xD;
          -  Have no pregnancy program and take effective contraceptive measures voluntarily&#xD;
&#xD;
          -  Abide by the experimental protocol and cooperate with the data collection according to&#xD;
             the researcher's judgment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with heart failure caused by other heart diseases,such as cor pulmonale,&#xD;
             congenital heart disease, primary pulmonary hypertension, secondary severe pulmonary&#xD;
             hypertension, severe stenosis or insufficiency of heart valves, cardiomyopathy&#xD;
             (including hypertrophic cardiomyopathy, restrictive cardiomyopathy, dilated&#xD;
             cardiomyopathy, alcoholic cardiomyopathy), moderate massive pericardial effusion,&#xD;
             constrictive pericarditis, infective endocarditis&#xD;
&#xD;
          -  Heart failure caused by systemic diseases or other systemic diseases, such as&#xD;
             rheumatic immune and secretory diseases;heart failure caused by kidney disease, lung&#xD;
             disease, liver disease and serious infection;heart failure caused by chemical or&#xD;
             toxicological causes&#xD;
&#xD;
          -  Patients who had acute myocardial infarction, underwent coronary revascularization or&#xD;
             left ventricular remodeling, underwent cardiac resynchronization with pacemaker&#xD;
             implantation, underwent cardiothoracic surgery within 3 months prior to receiving the&#xD;
             experimental drug, patients with other acute coronary syndrome, pulmonary embolism or&#xD;
             acute cerebrovascular disease&#xD;
&#xD;
          -  Severe arrhythmias such as ventricular tachycardia, second degree Ⅱ type or above&#xD;
             sinus atrial or atrioventricular block without pacemaker treatment, average QTc &gt;&#xD;
             500ms, heart rate &lt; 50 beats/min, etc&#xD;
&#xD;
          -  Complicated with other serious diseases, such as pheochromocytoma, hematologic&#xD;
             diseases, organ transplantation patients, and any history of malignant tumor&#xD;
&#xD;
          -  The presence of uncontrolled hypertension, systolic blood pressure ≥160mmHg and/or&#xD;
             diastolic blood pressure ≥100mmHg&#xD;
&#xD;
          -  Hypotension with a systolic blood pressure &lt;80mmHg and/or a diastolic blood pressure&#xD;
             &lt;50mmHg&#xD;
&#xD;
          -  Patients with hepatic and/or renal dysfunction (ALT≥ 2 times the upper limit of&#xD;
             normal, and/or estimated glomerular filtration rate (EGFR) &lt;30 mL /min/1.73m2&#xD;
&#xD;
          -  HbA1c ≥9.0%, or fasting blood glucose ≥13.9mmol/L&#xD;
&#xD;
          -  Moderate and severe anemia (Hb &lt; 90g/L)&#xD;
&#xD;
          -  Serum potassium ≥5.5mmol/L&#xD;
&#xD;
          -  Patients requiring anticoagulants who did not achieve dose stabilization for 1 month&#xD;
             or INR &gt; 3.0&#xD;
&#xD;
          -  In patients who need to take antiplatelet drugs, the dose was stable for less than 1&#xD;
             month, and the platelet value was lower than the lower limit of normal value&#xD;
&#xD;
          -  Allergic to the test drug or its related taste or ingredients&#xD;
&#xD;
          -  People with complicated mental illness, poor condition control and drug addiction&#xD;
&#xD;
          -  Unable to complete 6MWT&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Participation in other studies and use of investigational drugs from other studies&#xD;
             within 3 months prior to screening&#xD;
&#xD;
          -  The investigator deems that the patient is not suitable to participate in the study,&#xD;
             including the investigator's judgment that the patient is unable to complete the study&#xD;
             or comply with the requirements of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rui Liu</last_name>
    <phone>022-86343626</phone>
    <email>liurui2@tasly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guang'anmen Hospital, China Academy of Chinese Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiamen Hospital of Traditional Chinese Medicine</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lianfa Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated TCM Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suilin Ye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou University of Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhongqi Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhong Shan Hospital of Chinese Medicine</name>
      <address>
        <city>Zhongshan</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xueshan Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruikang Hospital Affiliated to Guangxi University of Traditional Chinese Medicine</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jingsong He</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Heilongjiang University of Chinese Medicine</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanyang Medical College</name>
      <address>
        <city>Nanyang</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jie Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pepole's Hospital of Xinzheng</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guangjun Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan University of Chinese Medicine</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yilin Mao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of University of South China</name>
      <address>
        <city>Hengyang</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jie Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanjing Hospital of Traditional Chinese Medicine</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ning Gu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ping Hou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ping Yao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Tianjin University of traditional Chinese Medicine</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qiang Xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital of Traditional Chinese Medicine of Xinjiang Uygur Autonomous Region</name>
      <address>
        <city>Ürümqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peng Li</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

